Figure 2
From: Does route of administration affect the outcome of TNF antagonist therapy?
![Figure 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Far996/MediaObjects/13075_2003_Article_1002_Fig2_HTML.jpg)
The efficacy of adalimumab (D2E7), as determined by tender and swollen joint counts, could be recognized within 2 weeks when the agent was injected intravenously (IV) but not until 12 weeks when injected subcutaneously (SC). Baseline values were standardized to 100%. Data on file, Abbott Laboratories, Abbott Park, IL, USA.